JP2021523225A5 - - Google Patents

Info

Publication number
JP2021523225A5
JP2021523225A5 JP2021510283A JP2021510283A JP2021523225A5 JP 2021523225 A5 JP2021523225 A5 JP 2021523225A5 JP 2021510283 A JP2021510283 A JP 2021510283A JP 2021510283 A JP2021510283 A JP 2021510283A JP 2021523225 A5 JP2021523225 A5 JP 2021523225A5
Authority
JP
Japan
Prior art keywords
compound according
group
formula
compound
ring
Prior art date
Application number
JP2021510283A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019213445A5 (https=
JP7379467B2 (ja
JP2021523225A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/030473 external-priority patent/WO2019213445A1/en
Publication of JP2021523225A publication Critical patent/JP2021523225A/ja
Publication of JPWO2019213445A5 publication Critical patent/JPWO2019213445A5/ja
Publication of JP2021523225A5 publication Critical patent/JP2021523225A5/ja
Application granted granted Critical
Publication of JP7379467B2 publication Critical patent/JP7379467B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021510283A 2018-05-03 2019-05-02 Rip1阻害剤化合物並びにそれを製造及び使用するための方法 Active JP7379467B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862666452P 2018-05-03 2018-05-03
US62/666,452 2018-05-03
PCT/US2019/030473 WO2019213445A1 (en) 2018-05-03 2019-05-02 Rip1 inhibitory compounds and methods for making and using the same

Publications (4)

Publication Number Publication Date
JP2021523225A JP2021523225A (ja) 2021-09-02
JPWO2019213445A5 JPWO2019213445A5 (https=) 2022-04-13
JP2021523225A5 true JP2021523225A5 (https=) 2022-04-13
JP7379467B2 JP7379467B2 (ja) 2023-11-14

Family

ID=66554488

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021510283A Active JP7379467B2 (ja) 2018-05-03 2019-05-02 Rip1阻害剤化合物並びにそれを製造及び使用するための方法

Country Status (38)

Country Link
US (3) US10975064B2 (https=)
EP (1) EP3788045B1 (https=)
JP (1) JP7379467B2 (https=)
KR (1) KR102823195B1 (https=)
CN (1) CN112384510B (https=)
AU (1) AU2019262142B2 (https=)
BR (1) BR112020022423A2 (https=)
CA (1) CA3099018A1 (https=)
CL (1) CL2020002840A1 (https=)
CO (1) CO2020015153A2 (https=)
CR (1) CR20200582A (https=)
CY (1) CY1126152T1 (https=)
DK (1) DK3788045T3 (https=)
DO (1) DOP2020000197A (https=)
EA (1) EA202092581A1 (https=)
EC (1) ECSP20077518A (https=)
ES (1) ES2947446T3 (https=)
FI (1) FI3788045T3 (https=)
HR (1) HRP20230909T1 (https=)
HU (1) HUE062277T2 (https=)
IL (1) IL278416B2 (https=)
JO (1) JOP20200277B1 (https=)
LT (1) LT3788045T (https=)
MA (1) MA52492B1 (https=)
MD (1) MD3788045T2 (https=)
MX (1) MX2020011622A (https=)
MY (1) MY205388A (https=)
PE (1) PE20210414A1 (https=)
PH (1) PH12020551848A1 (https=)
PL (1) PL3788045T3 (https=)
PT (1) PT3788045T (https=)
RS (1) RS64418B1 (https=)
SG (1) SG11202010913PA (https=)
SI (1) SI3788045T1 (https=)
SM (1) SMT202300203T1 (https=)
UA (1) UA128160C2 (https=)
WO (1) WO2019213445A1 (https=)
ZA (1) ZA202007487B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202092580A1 (ru) 2018-05-03 2021-04-07 Ригел Фармасьютикалз, Инк. Соединения, ингибирующие rip1, а также способы их получения и применения
UA128160C2 (uk) 2018-05-03 2024-04-24 Райджел Фармасутікалс, Інк. Сполуки, що інгібують rip1, а також способи їх одержання та застосування
CA3149926A1 (en) 2019-09-06 2021-03-11 Yan Chen Rip1 inhibitory compounds and methods for making and using the same
KR102793185B1 (ko) 2019-09-06 2025-04-09 리겔 파마슈티칼스, 인크. Rip1 억제 화합물 및 그를 제조 및 사용하는 방법
WO2021046515A1 (en) 2019-09-06 2021-03-11 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease
IL291665B2 (en) 2019-09-27 2025-07-01 Univ Texas Inhibitors of receptor interacting protein kinase i for the treatment of disease
AU2020378407B2 (en) * 2019-11-07 2024-02-01 Rigel Pharmaceuticals, Inc. Heterocyclic RIP1 inhibitory compounds
JP2023502514A (ja) * 2019-11-26 2023-01-24 ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム 疾患の処置のための受容体相互作用プロテインキナーゼiの阻害剤
AR121717A1 (es) * 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k
TWI840311B (zh) 2020-07-01 2024-04-21 美商雷傑製藥公司 Rip1k抑制劑
AU2021329777A1 (en) * 2020-08-18 2023-03-09 Hutchison Medipharma Limited Pyrimidinone compounds and uses thereof
AR125587A1 (es) 2021-03-11 2023-08-02 Rigel Pharmaceuticals Inc Inhibidores heterocíclicos de la quinasa de rip1
TW202311261A (zh) * 2021-05-14 2023-03-16 大陸商中國醫藥研究開發中心有限公司 氮呯類稠環化合物及其醫藥用途
CN115894489A (zh) * 2021-09-22 2023-04-04 中国药科大学 一种受体相互作用蛋白激酶1的抑制剂及其制备方法、应用
EP4422621A4 (en) * 2021-10-27 2025-08-27 Merck Sharp & Dohme Llc SPIROTRICYCLIC RIPK1 INHIBITORS AND METHODS OF USE THEREOF
KR20230100646A (ko) * 2021-12-24 2023-07-05 제일약품주식회사 Ripk1 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물
US20250179061A1 (en) * 2022-02-28 2025-06-05 Sironax Ltd. Rip1 modulators, preparations, and uses thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
EP0431519B1 (en) 1989-12-04 1994-06-15 G.D. Searle & Co. System for transdermal albuterol administration
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
DE69228827T2 (de) 1991-12-18 1999-10-21 Minnesota Mining And Mfg. Co., Saint Paul Mehrschichtige sperrstrukturen
EP0553769B1 (de) 1992-01-29 1996-01-03 FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG Ballspielschläger, insbesondere Tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
US20090099242A1 (en) 2007-08-15 2009-04-16 Cuny Gregory D Heterocyclic inhibitors of necroptosis
TWI648274B (zh) * 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類 (二)
US9725452B2 (en) 2013-03-15 2017-08-08 Presidents And Fellows Of Harvard College Substituted indoles and pyrroles as RIP kinase inhibitors
RU2017109122A (ru) * 2014-08-21 2018-09-21 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы
CN107207485A (zh) 2015-02-13 2017-09-26 葛兰素史密斯克莱知识产权发展有限公司 (S)‑5‑苄基‑N‑(5‑甲基‑4‑氧代‑2,3,4,5‑四氢苯并[b][1,4]氧氮杂环庚三烯‑3‑基)‑4H‑1,2,4‑三唑‑3‑甲酰胺的晶型
TWI763630B (zh) 2015-07-02 2022-05-11 瑞士商赫孚孟拉羅股份公司 雙環內醯胺及其使用方法
US10426758B2 (en) 2015-10-13 2019-10-01 Institut National De La Sante Et De La Recherche Medicale (Inserm) Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosis
JP6754772B2 (ja) 2015-10-23 2020-09-16 武田薬品工業株式会社 複素環化合物
WO2017109724A1 (en) 2015-12-21 2017-06-29 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
MA44007A (fr) * 2016-02-05 2018-12-19 Denali Therapeutics Inc Inhibiteurs du récepteur interagissant avec protéine kinase 1
EP3526219B1 (en) 2016-10-17 2021-12-15 F. Hoffmann-La Roche AG Bicyclic pyridone lactams and methods of use thereof
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
EP3585782A1 (en) 2017-02-27 2020-01-01 GlaxoSmithKline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
UA128160C2 (uk) 2018-05-03 2024-04-24 Райджел Фармасутікалс, Інк. Сполуки, що інгібують rip1, а також способи їх одержання та застосування
EA202092580A1 (ru) 2018-05-03 2021-04-07 Ригел Фармасьютикалз, Инк. Соединения, ингибирующие rip1, а также способы их получения и применения
EP3816163A4 (en) 2018-06-26 2022-04-13 Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences CELL NECROSIS INHIBITORS, METHOD OF MANUFACTURE THEREOF AND USE THEREOF
WO2020088194A1 (zh) 2018-11-02 2020-05-07 中国科学院上海药物研究所 抑制rip1激酶的杂环酰胺及其用途
KR102793185B1 (ko) 2019-09-06 2025-04-09 리겔 파마슈티칼스, 인크. Rip1 억제 화합물 및 그를 제조 및 사용하는 방법
CA3149926A1 (en) 2019-09-06 2021-03-11 Yan Chen Rip1 inhibitory compounds and methods for making and using the same
AU2020378407B2 (en) * 2019-11-07 2024-02-01 Rigel Pharmaceuticals, Inc. Heterocyclic RIP1 inhibitory compounds
AR121717A1 (es) 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k

Similar Documents

Publication Publication Date Title
JP2021523225A5 (https=)
TWI843372B (zh) 用於降解突變kras蛋白之化合物及其應用
KR102820455B1 (ko) Shp2 활성 억제용 화합물의 제조 방법
TWI877136B (zh) 化合物、組合物及方法
ES2453372T3 (es) Derivados de oxadiazol como agonistas de S1P1
HRP20230909T1 (hr) Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu
JPWO2019213445A5 (https=)
AU2018200461B2 (en) Process methods for phosphatidylinositol 3-kinase inhibitors
BR112020018064A2 (pt) Compostos de aminoácidos e métodos de uso
JP2018515581A5 (https=)
JP7187575B2 (ja) Rhoキナーゼ阻害剤としてのベンゾピラゾール系化合物
JP2004506611A5 (https=)
JP7797486B2 (ja) 新規なrho関連タンパク質キナーゼ阻害剤の調製方法およびその調製方法における中間体
UA127769C2 (uk) Похідні хіноліну як інгібітори інтегрину альфа-4-бета-7
JP2024530111A (ja) アフィカムテンを調製するための工程
RS59806B1 (sr) Postupci za pripremu citotoksičnih benzodiazepinskih derivata
WO2022232838A1 (en) Expanded dosage regimens for integrin inhibitors
JP4393376B2 (ja) フェニルシクロヘキシルプロパノールアミン誘導体、その製造法、およびその治療的適用
RU2011101661A (ru) Пиримидилсульфонамидное производное и его применение для лечения хемокин-опосредованных заболеваний
IL276852B1 (en) A process for making soluble guinelate cyclase beads
JP2016538337A5 (https=)
BR122025028707A2 (pt) Métodos para produção de compostos para inibir atividade de shp2
HK40095791A (en) Process of manufacture of a compound for inhibiting the activity of shp2
JP4782441B2 (ja) ジフェニルメチルピペラジン誘導体及びそれを含有する医薬組成物
CN120923507A (zh) 一种喹唑啉酮大环化合物及其制备方法和应用